Replies to post #23054 on The Rising Influence of Rising Affluence

[DewDiligence]

ZBH/VCEL—The difference in these companies’ markets may be moot now that an effective COVID vaccine is in sight.

[DewDiligence]

ZBH to spin-off dental/spine businesses—(two losers):

https://finance.yahoo.com/news/zimmer-biomet-announces-intent-spin-113100667.html

The spin-off company has yet to be named. Deal closing is targeted for mid-2022. The deal is tax-free for ZBH shareholders.

[DewDiligence]

ZBH on elective procedures:

https://www.fool.com/earnings/call-transcripts/2021/02/05/zimmer-biomet-holdings-inc-zbh-q4-2020-earnings-ca/

…unfortunately, this [COVID-19] pressure, in the corresponding decline and elective procedures, grew throughout Q4 and actually was worse at the end of December. And at this point, we expect that increase in pressure will continue throughout Q1 at least and will impact all three of our regions… So we would expect Q1 to be a little more challenging than even what we saw in Q4.

The good news, such as it is:

We expect that when that recovery occurs, we're going to see a period of what I would define as normal market growth augmented by deferred procedures that will be coming in as well. And we're going be ready for that, and we're excited about that.